Internal Reference Number: FOI_9358
Date Request Received: 22/04/2026 00:00:00
Date Request Replied To: 13/05/2026 00:00:00
This response was sent via: By Email
Request Summary: Asthma New Patients
Request Category: Companies
| Question Number 1: How many new patients were treated for Asthma by the Trusts Respiratory Department in the latest 4 month period (December - March 2026) with the treatments I have provided below? Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st August 2025, they can be classed as a new patient for the purposes of this question. 鈥� Cinqaero (Reslizumab) 鈥� Dupixent (Dupilumab) 鈥� Fasenra (Benralizumab) 鈥� Nucala (Mepolizumab) 鈥� Tezpire (Tezepelumab) 鈥� Xolair (Omalizumab) | |
| Answer To Question 1: There are no reportable patients for the drugs listed. | |
| Question Number 2: How many new patients were treated for Chronic Obstructive Pulmonary Disease (COPD) by the Trust鈥檚 Respiratory Department in the latest 4-month period (December - March 2026) with the treatments I have provided below? Please can you define a 鈥渘ew patient鈥� as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st August 2025, they can be classed as a new patient for the purposes of this question. 鈥� Dupixent (Dupilumab) 鈥� Nucala (Mepolizumab) | |
| Answer To Question 2: There are no reportable patients with this condition treated with these drugs. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
